Results 11 to 20 of about 357,544 (339)

Oscillatory dynamics in paclitaxel-proteinoid networks [PDF]

Discover Molecules
Paclitaxel is a widely used microtubule-targeting chemotherapeutic, yet its intrinsic electrochemical behavior remains poorly understood. Here we investigate the electrochemical and oscillatory properties of paclitaxel incorporated into proteinoid ...
Panagiotis Mougkogiannis, Andrew Adamatzky   +1 more
doaj   +2 more sources

Perbandingan Respon Terapi dan Toksisitas Regimen Kemoterapi Kombinasi antara Paclitaxel, Carboplatin, dan Ifosfamide (TIP) dengan Paclitaxel dan Carboplatin (TP) pada Kanker Serviks Stadium IIb

Obgynia, 2023
Tujuan: Mengetahui perbandingan respon terapi dan toksisitas regimen kemoterapi kombinasi Paclitaxel Carboplatin Ifosfamide dengan Paclitaxel Carboplatin pada kanker serviks stadium IIB.
Nagusman Danil, Sharvianty Arifuddin, Eddy Hartono, Nur Rakhmah, Ajardiana, Syahrul Rauf, Andi Alfian Zainuddin   +6 more
doaj   +1 more source

Way to efficient microbial paclitaxel mass production

Synthetic and Systems Biotechnology, 2023
The microbial synthesis of paclitaxel is attractive for its short-cycle, cost-effectiveness, and sustainability. However, low paclitaxel productivity, depleted capacity during subculture and storage, and unclear biosynthesis mechanisms restrain ...
Chenyue Li, Yanli Qi, Zhongke Sun, Mengwan Jiang, Chengwei Li   +4 more
doaj   +1 more source

Mining natural products related to paclitaxel reveals the possible biosynthetic pathway of paclitaxel [PDF]

BIO Web of Conferences, 2023
Paclitaxel is a widely used anti-tumor drug. Currently, paclitaxel can only be extracted from plants or synthesized by chemical semi-synthesis, which cause environmental damage and cannot meet the growing demand.
Sun Juncong, Deng Juntao, Song Xinfang, Gu Miao, Yang Weiyang, Liu Min   +5 more
doaj   +1 more source

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Frontiers in Oncology, 2022
Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently
Zhichao Tian, Weitao Yao
doaj   +1 more source

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Annals of Oncology, 2021
BACKGROUND In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in ...
D. Miles, J. Gligorov, F. André, D. Cameron, A. Schneeweiss, C. Barrios, B. Xu, A. Wardley, D. Kaen, L. Andrade, V. Semiglazov, M. Reinisch, S. Patel, M. Patre, L. Morales, S. Patel, M. Kaul, T. Barata, J. O’Shaughnessy, Q. Zhang, Z. Shao, X. Wang, C. Geng, X. Yan, Z. Tong, K. Shen, Y. Yin, T. Sun, J. Yang, J. Feng, Ming Yan, Y. Wang, Q. Liu, S. Zhang, M. De Laurentiis, A. Santoro, V. Guarneri, M. Colleoni, C. Natoli, L. Cortesi, S. Placido, L. Gianni, F. Ferraù, L. Livi, A. Zambelli, L. Del Mastro, G. Tonini, F. Montemurro, G. Bianchi, R. Pedersini, S. Prete, G. Allegrini, G. Naso, P. Vici, D. Loirat, A. Mailliez, F. Priou, O. Tredan, F. Dalenc, C. Perrin, M. Timar David, N. Dohollou, L. Teixeira, F. Brocard, A. Arnaud, S. Delaloge, J. Spano, L. Mansi, F. Damian, J. Pedrini, S. Aleixo, R. Hegg, R. Junior, M. Schmidt, C. Wenzel, E. Grischke, M. Just, N. Harbeck, C. Schumacher, U. Peters, D. Fischer, H. Forstbauer, R. Liersch, E. Warner, N. Bouganim, C. Doyle, J. P. Price Hiller, T. Vandenberg, M. Pavic, A. Robinson, G. Roldan Urgoiti, N. Califaretti, A. Alacacıoğlu, M. Gumus, B. Yalcin, I. Çiçin, F. Kose, K. Uygun, M. Kaplan, E. Çubukçu, M. Harries, D. Doval, S. Gupta, P. Mohapatra, S. Chatterjee, N. Ghadyalpatil, M. Singhal, S. Nag, A. Agarwal, I. Wolf, E. Gal Yam, R. Yerushalmi, T. Peretz, G. Fried, N. Ben Baruch, D. Katz, E. Hamilton, F. Kayali, A. Brufsky, M. Telli, G. Wright, R. Oyola, T. Rakowski, S. Graff, S. Tjulandin, A. Aparicio, M. Ruíz Borrego, L. Merino, J. Guerra Martinez, E. López, T. Yamashita, S. Ohtani, K. Inoue, Y. Ito, N. Niikura, T. Nakayama, Y. Sagara, Y. Yanagita, Y. Kamada, K. Kaneko, A. Nervo, A. Eniu, M. Schenker, P. Priester, B. Melichar, M. Zimovjanova, P. Sormova, J. Šufliarský, M. Kakalejcik, R. Belbaraka, H. Errihani, D. Le Than, D. Pham, G. Aravantinos, C. Papadimitriou, G. Koumakis, C. Papandreou, P. Podolski, K. Tabane   +158 more
semanticscholar   +1 more source

Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells

BMC Cancer, 2021
Background Paclitaxel (Taxol) is a microtubule-stabilizing drug used to treat several solid tumors, including ovarian, breast, non-small cell lung, and pancreatic cancers.
Celina Amaya, Shihua Luo, Julio Baigorri, Rogelio Baucells, Elizabeth R. Smith, Xiang-Xi Xu   +5 more
doaj   +1 more source

Synthetic biology identifies the minimal gene set required for Paclitaxel biosynthesis in a plant chassis.

Molecular Plant, 2023
The diterpenoid paclitaxel (Taxol®) is a chemotherapy medication widely used as a first-line treatment against several types of solid cancers. The supply of paclitaxel from natural sources is limited.
You-Qing Zhang, Lorenz Wiese, Hao Fang, S. Alseekh, Leonardo Perez de Souza, F. Scossa, John J Molloy, Mathias Christmann, A. Fernie   +8 more
semanticscholar   +1 more source

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer

Frontiers in Oncology, 2022
ObjectiveWe conducted a phase 2 trial to compare the safety and efficacy of intravenous paclitaxel or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 in untreated advanced gastric cancer.MethodsParticipants with untreated advanced gastric cancer ...
Shen Zhao, Shen Zhao, Liyu Su, Yigui Chen, Xiaofeng Li, Peicheng Lin, Wujin Chen, Wenzheng Fang, Jinfeng Zhu, Hui Li, Liping Ren, Jie Liu, Yanni Hong, Shaowei Lin, Nanfeng Fan, Rongbo Lin, Rongbo Lin   +16 more
doaj   +1 more source

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

Cancer Cell, 2021
The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib added to standard paclitaxel neoadjuvant chemotherapy (durvalumab/olaparib/paclitaxel [DOP]) was investigated in the phase II I-SPY2 trial of stage II/III HER2-negative breast ...
L. Pusztai, C. Yau, D. Wolf, H. Han, L. Du, A. Wallace, Erica String-Reasor, J. Boughey, A. Chien, A. Elias, H. Beckwith, R. Nanda, K. Albain, A. Clark, K. Kemmer, K. Kalinsky, C. Isaacs, Alexandra Thomas, R. Shatsky, T. Helsten, A. Forero-Torres, Minetta C. Liu, L. Brown-Swigart, E. Petricoin, J. Wulfkuhle, S. Asare, Amy Wilson, R. Singhrao, L. Sit, G. Hirst, S. Berry, A. Sanil, A. Asare, J. Matthews, J. Perlmutter, M. Melisko, H. Rugo, R. Schwab, W. Symmans, D. Yee, L. V. van’t Veer, N. Hylton, A. DeMichele, D. Berry, L. Esserman   +44 more
semanticscholar   +1 more source